Feasibility of Long-term Proteasome Inhibition in Multiple Myeloma by in-class Transition From Bortezomib to Ixazomib
Sudhir Manda(Dartmouth–Hitchcock Medical Center), Robert M. Rifkin(Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo), Kimberly Bogard(Millennium Engineering and Integration (United States)), Suman Kambhampati(Veterans Health Administration), Vickie Lu(Millennium Engineering and Integration (United States)), Habte Yimer(Texas Oncology), Roger M. Lyons(Hematology Oncology Associates), Saulius Girnius(TriHealth), Veena Charu, Brittany Demers(Millennium Engineering and Integration (United States)), Stephen J. Noga, Christopher A. Yasenchak(Willamette Valley Cancer Institute and Research Center), Ruemu Birhiray(The US Oncology Network), Renda H. Ferrari(Millennium Engineering and Integration (United States)), Dasha Cherepanov(Millennium Engineering and Integration (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Haresh Jhangiani(Compassionate Cancer Care), Presley Whidden(Millennium Engineering and Integration (United States)), Jack Aiello(Empowerment Program)
Cited by 16
Related Papers
Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial
|The Lancet|2008|862
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
|Breast Cancer Research and Treatment|2017|761
Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials
|European Journal of Cancer|2012|588
AMG 531, a Thrombopoiesis-Stimulating Protein, for Chronic ITP
|New England Journal of Medicine|2006|530
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2022|453